APA (7th ed.) Citation

Callander, N., Markovina, S., Eickhoff, J., Hutson, P., Campbell, T., Hematti, P., . . . Miyamoto, S. (2014). Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: A study from the Wisconsin Oncology Network. Cancer chemotherapy and pharmacology, 74(4), 875-882. https://doi.org/10.1007/s00280-014-2550-5

Chicago Style (17th ed.) Citation

Callander, Natalie, et al. "Acetyl-l-carnitine (ALCAR) for the Prevention of Chemotherapy-induced Peripheral Neuropathy in Patients with Relapsed or Refractory Multiple Myeloma Treated with Bortezomib, Doxorubicin and Low-dose Dexamethasone: A Study from the Wisconsin Oncology Network." Cancer Chemotherapy and Pharmacology 74, no. 4 (2014): 875-882. https://doi.org/10.1007/s00280-014-2550-5.

MLA (9th ed.) Citation

Callander, Natalie, et al. "Acetyl-l-carnitine (ALCAR) for the Prevention of Chemotherapy-induced Peripheral Neuropathy in Patients with Relapsed or Refractory Multiple Myeloma Treated with Bortezomib, Doxorubicin and Low-dose Dexamethasone: A Study from the Wisconsin Oncology Network." Cancer Chemotherapy and Pharmacology, vol. 74, no. 4, 2014, pp. 875-882, https://doi.org/10.1007/s00280-014-2550-5.